Glenmark gets marketing approval for its Nasal Spray in 13 countries

Allergic rhinitis is both widespread and underreported, making it challenging to diagnose and treat in time.

Nasal Spray Medicine
Picture: Pixabay

Last Updated on October 2, 2021 by The Health Master

Glenmark Pharmaceuticals has received marketing approval for its fixed-dose combination nasal spray Ryaltris in 13 countries across the EU and the UK. The company is set to launch Ryaltris directly in the markets of Czech Republic, Slovakia, Poland and the UK.

Ryaltris will be marketed in the rest of Europe by the Menarini Group as part of its exclusive licensing agreement with Glenmark. Ryaltris (olopatadine 665 µg and mometasone furoate 25 µg), is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.

Ryaltris relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes, a company statement said.

Commenting on this development, Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals, said, “Allergic rhinitis is both widespread and underreported, making it challenging to diagnose and treat in time.

It impacts a person’s quality of life and can lead to functional impairments, while also increasing the risk of asthma. This marketing approval will pave the way for the effective and timely treatment of allergic rhinitis for thousands of patients across Europe.

We are already seeing its therapeutic benefits in other regions where Ryaltris has been launched, and we hope to extend this relief to more people across the world.”

Glenmark has also partnered with Hikma Pharmaceuticals and Bausch Health for the commercialisation of Ryaltris in the US and Canada, respectively. In April this year, Glenmark concluded the DCP regulatory procedure in Europe, enabling approval in 17 countries across the EU and the UK, added the statement.

Zydus Cadila gets USFDA nod for drug to treat Psoriasis

Zydus Cadila gets USFDA nod for Antidepressant drug

Zydus Cadila gets tentative nod from USFDA for Brexpiprazole tablets

USFDA to review use of Blood Disorder Therapy in children

Aleor gets USFDA final approval for Metronidazole gel

Dr Reddy’s Labs gets USFDA nod for generic Librax capsules

Maharashtra FDA issues stop sale order to 246 pharmacies

Companies charging these ceiling price not under its purview: NPPA clarifies

FDA to check food licenses of all street vendors

Lupin launches Droxidopa capsules

Pfizer to soon submit data on C-19 vaccine for kids aged…

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon